Literature DB >> 29106355

Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.

Albert Farrugia1, Megha Bansal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29106355      PMCID： PMC6343589          DOI： 10.2450/2017.0160-17

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  3 in total

1.  High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.

Authors:  Andrea Messori; Flora Peyvandi; Sabrina Trippoli; Roberta Palla; Frits R Rosendaal; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2017-05-15       Impact factor: 3.443

2.  Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

Authors:  Sean D Sullivan; Josephine A Mauskopf; Federico Augustovski; J Jaime Caro; Karen M Lee; Mark Minchin; Ewa Orlewska; Pete Penna; Jose-Manuel Rodriguez Barrios; Wen-Yi Shau
Journal:  Value Health       Date:  2013-12-13       Impact factor: 5.725

3.  Impact of inhibitors on hemophilia A mortality in the United States.

Authors:  Christopher E Walsh; J Michael Soucie; Connie H Miller
Journal:  Am J Hematol       Date:  2015-02-05       Impact factor: 10.047
  3 in total
  1 in total

1.  Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".

Authors:  Andrea Messori; Flora Peyvandi; Sabrina Trippoli; Roberta Palla; Frits R Rosendaal; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2017-12-22       Impact factor: 3.443
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.